New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 20, 2012
11:08 EDTDANOY, PFE, MJN, SYUT, NSRGYDanone drops following report of raised bid for Pfizer unit
Groupe Danone (DANOY) is retreating after the French food maker increased its offer for Pfizer's (PFE) infant nutrition business to close to $11B, according to Reuters, which cited the French website WanSquare. Danone is trying to outbid Nestle (NSRGY), which was nearing a deal for the Pfizer unit last week, Reuters reported, citing unnamed sources. Pfizer's infant nutrition business is growing quickly and is strong in emerging markets, with a key position in China, Reuters added. In late morning trading, Danone dropped 27c, or 1.91%, to $13.89. Pfizer (PFE) is climbing, while Mead Johnson (MJN) and Synutra (SYUT), which also sell infant formula, advanced.
News For DANOY;PFE;MJN;SYUT;NSRGY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 17, 2014
12:57 EDTDANOY, MJNDanone to pursue takeover of Mead Johnson, sources say, Reuters reports
Subscribe for More Information
12:48 EDTMJNMead Johnson calls active on Danone will pursue takeover report
Subscribe for More Information
12:36 EDTDANOY, MJNDanone will pursue Mead Johnson takeover, sources say, Reuters reports
Subscribe for More Information
October 16, 2014
08:38 EDTPFEBaxter expects divestiture of vaccines business to Pfizer to close in Q4
Subscribe for More Information
08:08 EDTPFEActavis confirms generic Quillivant XR patent challenge
Subscribe for More Information
07:28 EDTPFEFDA to hold a joint advisory committee meeting on Chantix
Subscribe for More Information
05:29 EDTNSRGYNestle reports FY outlook unchanged
Subscribe for More Information
05:28 EDTNSRGYNestle reports 9 month sales of CHF 66.2B
Subscribe for More Information
October 15, 2014
15:00 EDTPFEShire-Allergan, AbbVie-Pfizer deals possible if merger scrapped, Bloomberg says
Subscribe for More Information
08:28 EDTDANOYDanone reports Q3 like-for-like sales up 6.9% to EU 5.42B
Danone confirmed its 2014 targets of sale growth between 4.5%-5.5%, trading operating margin stable within a range of down 20bps and up 20bps and free cash-flow of around EU 1.5B excluding exceptional items.
October 14, 2014
11:23 EDTPFEBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
October 13, 2014
08:01 EDTPFEPfizer announces FDA acceptance of Palbociclib NDA with priority review
Subscribe for More Information
October 10, 2014
08:39 EDTSYUTSynutra sees FY15 revenue $450M-$500M
Subscribe for More Information
08:39 EDTSYUTSynutra sees Q2 revenue $106M-$110M, Q2 net income $9M-$10M
These positive results were due to increased IMF sales at the distributor and retail channels.
08:06 EDTPFEPfizer presents Staphylococcus aureus vaccine Phase 1, Phase 2 study data
Subscribe for More Information
October 8, 2014
10:55 EDTPFELeerink pharmaceuticals analyst holds an analyst/industry conference call
Analysts discuss prospects for drugs that raise HDL cholesterol, effects of CETP mechanism, expectations for REVEAL data and the potential place for CETP inhibitors in a crowded hypersholesterolemia landscape on an Analyst/Industry conference call to be held on October 9 at 11 am.
08:09 EDTPFEPfizer presents LP2086 Phase 2 study data
Pfizer announced it will present the results of a Phase 2, randomized study to evaluate co-administration of the company’s investigational meningococcal group B vaccine, bivalent recombinant LP2086, or rLP2086, with a licensed quadrivalent human papillomavirus vaccine at IDWeek 2014. Data demonstrated immune responses to both vaccines were generated after concomitant administration of bivalent rLP2086 and HPV4. Prespecified noninferiority criteria were met for the bivalent rLP2086 antigens studied and three of the four antigens for HPV4. Primary immunogenicity endpoints, measured after the third dose, included geometric mean titers against HPV antigens in Groups 1 and 3 and human complement serum bactericidal assay GMTs against meningococcal group B disease test strains in Groups 1 and 2. Secondary immunogenicity endpoints included the rate of seroconversion to HPV antigens. Safety of bivalent rLP2086 was assessed after concomitant administration with HPV4 or saline. The prespecified noninferiority criteria were met for three of four HPV antigens and both meningococcal group B disease test strains. Seroconversion for all four HPV antigens was achieved by 99% or more of the subjects for the groups that received HPV4 concomitantly with bivalent rLP2086 or with saline. More local reactions occurred following administration of bivalent rLP2086 compared with saline but the incidence of these reactions did not increase with subsequent vaccine administration. The rates of local and systemic reactions were comparable when bivalent rLP2086 was given with HPV4 to bivalent rLP2086 given alone.
07:19 EDTPFECBI to hold a conference
Subscribe for More Information
07:18 EDTPFEInfectious Diseases Society of America to hold a conference
ID Week 2014 is being held in Philadelphia on October 8-12.
October 7, 2014
07:48 EDTPFEU.S. Chamber of Commerce to hold a discussion
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use